Finch Therapeutics Group, Inc. financial data

Symbol
FNCH on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
75 State Street, Suite 100, Boston, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 557 % +16.5%
Debt-to-equity 157 % +99.5%
Return On Equity -69.1 % +64.7%
Return On Assets -26.9 % +75.5%
Operating Margin -78.4K % -484%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.61M shares +0.06%
Common Stock, Shares, Outstanding 1.61M shares +0.06%
Entity Public Float 9.1M USD -88%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.61M shares +0.06%
Weighted Average Number of Shares Outstanding, Diluted 1.61M shares +0.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 0 USD -100%
General and Administrative Expense 19.7M USD -47%
Operating Income (Loss) -19.5M USD +86.5%
Nonoperating Income (Expense) 5.34M USD +36.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14.2M USD +89.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -14.2M USD +89.6%
Earnings Per Share, Basic -8.49 USD/shares +91.6%
Earnings Per Share, Diluted -8.49 USD/shares +91.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16M USD -52.9%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 17.3M USD -52.7%
Property, Plant and Equipment, Net 507K USD -30.7%
Operating Lease, Right-of-Use Asset 25.4M USD -6.84%
Goodwill 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 45.6M USD -31.8%
Accounts Payable, Current 29K USD -93.3%
Liabilities, Current 4.46M USD -53.4%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 26.9M USD -8.48%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 31.4M USD -19.5%
Retained Earnings (Accumulated Deficit) -359M USD -4.11%
Stockholders' Equity Attributable to Parent 14.2M USD -49%
Liabilities and Equity 45.6M USD -31.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +67.4%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.61M shares +0.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.36M USD +85.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.4M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 202K USD +10000%
Deferred Tax Assets, Valuation Allowance 86.4M USD +14.3%
Deferred Tax Assets, Gross 102M USD +14.3%
Depreciation 1.4M USD +7.69%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 39.6M USD
Property, Plant and Equipment, Gross 869K USD -96.6%
Operating Lease, Liability, Current 2.09M USD +26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.07M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.93M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.22M USD
Deferred Tax Assets, Operating Loss Carryforwards 73.7M USD +19.3%
Unrecognized Tax Benefits 3.57M USD +44.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.36M USD
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 4.93M USD -21.2%
Depreciation, Depletion and Amortization 43K USD -96.9%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 3.2M USD -30%
Deferred Tax Assets, Net of Valuation Allowance 15.6M USD +14.6%
Share-based Payment Arrangement, Expense 492K USD -90.8%
Operating Leases, Future Minimum Payments, Due in Three Years 5.07M USD -21.1%
Operating Leases, Future Minimum Payments Due 40.8M USD -19.3%